Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1981 1
1982 3
1983 1
1984 8
1985 5
1986 4
1987 3
1988 9
1989 3
1990 14
1991 15
1992 16
1993 15
1994 34
1995 30
1996 36
1997 33
1998 27
1999 45
2000 52
2001 83
2002 79
2003 107
2004 119
2005 143
2006 144
2007 197
2008 237
2009 266
2010 312
2011 374
2012 474
2013 512
2014 594
2015 660
2016 661
2017 742
2018 906
2019 1050
2020 1258
2021 1298
2022 1505
2023 1598
2024 1270
2025 2

Text availability

Article attribute

Article type

Publication date

Search Results

13,417 results

Results by year

Filters applied: . Clear all
Page 1
Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.
Ji H, Zhao X, Chen X, Fang H, Gao H, Wei G, Zhang M, Kuang H, Yang B, Cai X, Su Y, Piao C, Zhao S, Li L, Sun W, Xu T, Xu Q, Fan Y, Ye J, Yao C, Shang M, Song G, Chen L, Zheng Q, Xiao X, Yan L, Lian F, Tong X, Jia Z; FOCUS Trial Committees and Investigators. Ji H, et al. Among authors: ye j. JAMA Intern Med. 2024 Jul 1;184(7):727-735. doi: 10.1001/jamainternmed.2024.1190. JAMA Intern Med. 2024. PMID: 38829648 Free PMC article. Clinical Trial.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. Bumma N, et al. Among authors: ye jc. J Clin Oncol. 2024 Aug 1;42(22):2702-2712. doi: 10.1200/JCO.24.01008. Epub 2024 Jun 16. J Clin Oncol. 2024. PMID: 38879802 Free PMC article. Clinical Trial.
Exosome-based nanoparticles and cancer immunotherapy.
Ye J, Li D, Jie Y, Luo H, Zhang W, Qiu C. Ye J, et al. Biomed Pharmacother. 2024 Aug 20;179:117296. doi: 10.1016/j.biopha.2024.117296. Online ahead of print. Biomed Pharmacother. 2024. PMID: 39167842 Free article. Review.
SERSomes for metabolic phenotyping and prostate cancer diagnosis.
Bi X, Wang J, Xue B, He C, Liu F, Chen H, Lin LL, Dong B, Li B, Jin C, Pan J, Xue W, Ye J. Bi X, et al. Among authors: ye j. Cell Rep Med. 2024 Jun 18;5(6):101579. doi: 10.1016/j.xcrm.2024.101579. Epub 2024 May 21. Cell Rep Med. 2024. PMID: 38776910 Free PMC article.
Targeted protein degradation systems to enhance Wnt signaling.
Sampathkumar P, Jung H, Chen H, Zhang Z, Suen N, Yang Y, Huang Z, Lopez T, Benisch R, Lee SJ, Ye J, Yeh WC, Li Y. Sampathkumar P, et al. Among authors: ye j. Elife. 2024 Jun 7;13:RP93908. doi: 10.7554/eLife.93908. Elife. 2024. PMID: 38847394 Free PMC article.
Focus on negatively regulated NLRs in inflammation and cancer.
Wang J, He W, Li C, Ma Y, Liu M, Ye J, Sun L, Su J, Zhou L. Wang J, et al. Among authors: ye j. Int Immunopharmacol. 2024 Jul 30;136:112347. doi: 10.1016/j.intimp.2024.112347. Epub 2024 May 30. Int Immunopharmacol. 2024. PMID: 38820966 Free article. Review.
13,417 results
You have reached the last available page of results. Please see the User Guide for more information.